trastuzumab envedotin (DP303c) / CSPC Pharma  >>  Phase 1
Welcome,         Profile    Billing    Logout  

2 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
trastuzumab envedotin (DP303c) / CSPC Pharma
NCT04146610: Study of DP303c Administered Intravenously to Subjects With HER2-Positive in Advanced Solid Tumors

Unknown status
1
30
RoW
an antibody drug conjugate, ADC
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Neoplasms
06/21
06/21
NCT05810103: A Study of DP303c in Patients With HER2-positive Advanced Solid Tumors

Recruiting
1
12
RoW
DP303c
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
HER2-positive Advanced Solid Tumors
12/23
03/24

Download Options